If you have money sitting in your FSA, the clock is ticking. Most plans have a "use it or lose it" policy, meaning unused funds disappear at year-end. Therapy is an eligible expense, and even if ...

State Medicaid agencies are struggling to pay for intensive therapy for children with autism—and looming federal Medicaid cuts are likely to make the problem worse. Parents of children and young ...

Nvidia (NVDA) stock fell along with the broader market on Thursday, despite the chipmaker posting better-than-expected third quarter earnings and providing a strong outlook for the current quarter a ...

INDIANAPOLIS (INDIANA CAPITAL CHRONICLE) — Parents of autistic children — and ABA therapy providers — may soon encounter new usage limits, reimbursement rates and other changes as Indiana attempts to ...

Curaleaf's third-quarter revenue fell 3% year over year to USD 320 million. International revenue contributed USD 46 million, a 56% increase, but failed to offset domestic revenue's 9% decline to USD ...

D.R. Horton, America’s largest homebuilder, is doubling down on mortgage rate buydowns in order to keep its sales volumes up amid an affordability-strained housing market. On its October 28 earnings ...

Automation will help the cell therapy sector reduce the number of expert staff needed to manufacture these lifesaving therapies, thereby making them more affordable. A team, led by researchers at the ...

Millions of Americans are bracing themselves for a significant hike in their 2026 health insurance premiums without the subsidies at the center of the government shutdown battle. It comes as insurance ...

Forbes contributors publish independent expert analyses and insights. Analyzing tech stocks through the prism of cultural change. The investment community is currently misreading the most important ...

Oct 10 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday.

(Reuters) -Novo Nordisk has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday. Bloomberg News first reported on ...